Seattle Genetics (SGEN) Tops Q3 EPS by 8c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day losing streak as stocks reclaim some shine
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Seattle Genetics Reports Third Quarter 2017 Financial Results
October 26, 2017 4:02 PM EDT-Third Quarter 2017 Revenues Were $135.3 Million, Including $79.2 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales-
-FDA Breakthrough Therapy Designation Granted for ADCETRIS in Combination with Chemotherapy for Frontline Advanced Classical Hodgkin Lymphoma; Supplemental Biologics License Application on Track for Submission in the Fourth Quarter of 2017-
-Full Data from ADCETRIS Phase 3 ECHELON-1 Trial Accepted for Presentation at ASH Annual Meeting-
-Pivotal Trial Initiated of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer-
-Conference Call Today at 4:30... More
